S&P Futures
5,966.75 +8.50 (+0.14%) Dow Futures
43,984.00 +83.00 (+0.19%) Nasdaq Futures
20,939.50 +45.50 (+0.22%) Russell 2000 Futures
2,410.10 +4.30 (+0.18%) Crude Oil
71.66 -0.03 (-0.04%) Gold
2,667.50 -8.80 (-0.33%)
| Previous Close | 6.86 |
| Open | 6.91 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 6.86 - 7.29 |
| 52 Week Range | 6.50 - 23.50 |
| Volume | |
| Avg. Volume | 38,372 |
| Market Cap | 9.206M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -19.11 |
| Earnings Date | Nov 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.00 |
GlobeNewswireGalecto Reports Third Quarter 2024 Financial Results
- Completed strategic review to focus on oncology and severe liver diseases - Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge Medicines - Appointed Dr. Amy Wechsler to the Board of Directors and Matthew Kronmiller as Executive Vice President of Strategy and Chief Business Officer BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the devel
TipRanksGalecto price target raised to $10 from $9 at Oppenheimer
Oppenheimer raised the firm’s price target on Galecto to $10 from $9 and keeps an Outperform rating on the shares after speaking with management following the completion of its strategic transaction that prioritizes focus on oncology and liver diseases by leveraging GB1211 while bolstering the pipeline. The firm sees Galecto’s equity-financed acquisition of global rights to BRM-1420 as providing a differentiated asset with financial efficiency that meanwhile enables continued development of GB12
